The Journal

20 long-form pieces on what tirzepatide telehealth costs and how to verify it, each computed from the tracked dataset.

Direct answer

20 analyses, each answering one question and carrying its own table and chart computed from the dataset rather than illustrated from stock.

Where a piece states a price it carries the capture date and evidence status, and where it makes a regulatory or clinical claim it links the primary source.

First-year all-in cost

NexLife$2,580Yucca Health$3,096IVIM Health$3,219ShedRx$3,318Mochi Health$3,336Found$3,468SkinnyRx$3,588Amble Health$3,600Lavender Sky Health$3,971Henry Meds$4,188TrimRx$4,188Join Fridays$4,308
Two months of titration plus ten at a 10 mg maintenance dose, membership included. Captured 2026-08-05.

Every piece in the journal

Analysis · 2026-08-06

Cheapest Tirzepatide Telehealth in 2026

Entry prices and annual costs rank differently. Here is the whole tracked market on both axes, with the evidence status attached to every figure.

Guide · 2026-08-06

Tirzepatide Cost Without Insurance

Compounded telehealth, manufacturer self-pay and retail, priced on one basis at the dose you will actually hold.

Analysis · 2026-08-06

Compounded vs Brand Tirzepatide Cost

The gap has narrowed sharply. Here is what the approved product costs against the compounded route at every dose.

Data · 2026-08-05

Tirzepatide Price Per Milligram

Monthly prices are not comparable between a patient at 2.5 mg and one at 15 mg. Dividing by milligrams delivered removes the dose entirely.

Investigation · 2026-08-05

Hidden Fees in GLP-1 Telehealth

Membership, shipping, consultation, labs, refills, dose upcharges, cancellation, promotional reversion and prepaid forfeiture.

Analysis · 2026-08-05

Flat Rate vs Dose-Based Pricing

One model reprices you as the dose climbs and one does not. The crossover is the number nobody publishes.

Guide · 2026-08-04

Is a Twelve-Month Plan Worth It?

The discount is real and so is the forfeiture. What a prepaid term saves, and what it puts beyond recall during titration.

Guide · 2026-08-04

How to Verify a Compounding Pharmacy

Five checks against public registers, none requiring clinical training, all completed before you hand over a medical history.

Guide · 2026-08-04

Tirzepatide Telehealth Red Flags

Two of them should end the conversation on their own, whatever else a programme discloses.

Guide · 2026-08-03

Switching Tirzepatide Providers

The saving is easy to calculate. The two switching costs that undo it are not.

Data · 2026-08-03

The Cost of Dose Escalation

On dose-scaled programmes your bill rises exactly as the dose starts working. Here is the increase, in dollars.

Analysis · 2026-08-03

GLP-1 Membership Fees Explained

A recurring platform charge is invisible in the advertised number and unavoidable in the number you pay.

Guide · 2026-08-02

Cancelling a GLP-1 Subscription

Usually nothing, once medication has shipped. What to establish before you pay, and the notice periods that decide it.

Guide · 2026-08-02

Appealing a Tirzepatide Denial

One can be overturned on medical necessity and one cannot. Establishing which you face saves weeks.

Coverage · 2026-08-02

Medicare and Tirzepatide

For eligible beneficiaries this now undercuts every compounded route we track, which inverts the usual advice.

Guide · 2026-08-01

Tirzepatide State Availability

Two licences have to line up for any shipment, and neither is about you.

Guide · 2026-08-01

Cold Chain and Warm Shipments

Do not inject, do not decide alone, and do not accept a replacement policy you were never shown.

Explainer · 2026-08-01

Is Compounded Tirzepatide Legal?

Lawful under a statutory pathway, not FDA-approved, and narrower than it was two years ago. Three separate facts.

Analysis · 2026-07-31

Tirzepatide vs Semaglutide Cost

The head-to-head favours tirzepatide on effect size. Whether it favours your budget depends on the dose you hold.

Analysis · 2026-07-31

When a Provider Leaves the Market

Five of the largest names stopped selling compounded tirzepatide during 2026. Patients found out at renewal.

Reading a price like a clinician would

A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?

Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.

None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.

What the GIP arm may be doing

GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.

This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.

The question worth asking before the price question

Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.

Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.

Primary sources

Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.

  1. FDA — Human Drug Compounding
  2. FDA — Compounding and the FDA: Questions and Answers
  3. FTC — Health Products Compliance Guidance
  4. FTC — Endorsement and testimonial guidance
  5. NABP — State Boards of Pharmacy directory

Next step

Compare every programme on one screen

The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.

Open the comparison matrix How all-in cost is calculated